2023 the Japanese Society of Medical Oncology Annual Meeting – The 20th Anniversary Meeting –

2023 the Japanese Society of Medical Oncology Annual Meeting – The 20th Anniversary Meeting –

Call for Abstracts

Updated Friday, December 8, 2022

The submission for the final, updated late-breaking data for Late-breaking Abstract is now open.
E-mail notification has been sent to those who have already made a provisional registration. Please check your e-mail and submit your abstract by the deadline.

Deadline for submitting the final, updated late-breaking data:
Thursday, December 22, 2022, 5:00 p.m. (JST)

If you wish to submit a new abstract, or if you have difficulty in submitting your abstract by the above deadline, please contact the abstract submission section of Congress Secretariat (endai-jsmo2023[A]convention[D]co[D]jp( Please change [A]to @ and [D] to . )).

If you are Japanese, please declare your COI and
submit your abstract to the Japanese website.

Abstract Submission Period

Noon, Wednesday, June 15, 2022 – Noon, Thursday, September 15, 2022 (JST)
Friday, September 30, 2022 (JST)
Extended until Fri, Sep 30. We look forward to your submissions!
Abstract Submission has been closed. Thank you for your submission!
Noon, Wednesday, June 15, 2022 – Noon, Thursday, September 15, 2022 (JST)
Friday, September 30, 2022 (JST)
Extended until Fri, Sep 30. We look forward to your submissions!
Abstract Submission has been closed.
Thank you for your submission!

Call for Abstracts

General Abstract (Oral / Poster Presentation)

JSMO2023 accepts abstracts for General Abstract.
The Oral and Poster presentations will be basically given and held on-site.

Please select the abstract category from the list below. (The 1st & 2nd choices are required.)

Category Sub-Category Presentation Style
01.
Gastrointestinal Cancer
01-01
Esophageal Cancer
01-02
Gastric Cancer
01-03
Small Bowel Cancer
01-04
Colorectal Cancer
01-05
Other (Appendix Cancer, Anal Cancer, etc.)
Oral / Poster
02.
Hepatobiliary / Pancreatic Cancer
02-01
Liver Cancer
02-02
Gallbladder and Biliary Tract Cancer
02-03
Pancreatic Cancer
Oral / Poster
03.
Lung Cancer / Thoracic Cancer
03-01
Early Stage Non-Small Cell Lung Cancer / Perioperative Treatment
03-02
Locally Advanced Non-Small Cell Lung Cancer
03-03
Metastatic Non-Small Cell Lung Cancer / Chemotherapy
03-04
Metastatic Non-Small Cell Lung Cancer / Tyrosine Kinase Inhibitor
03-05
Metastatic Non-Small Cell Lung Cancer / Immunotherapy
03-06
Small Cell Lung Cancer
03-07
Other (Mesothelioma, Thymic Malignancies, etc.)
Oral / Poster
04.
Hematologic Malignancies
04-01
Lymphoma
04-02
Leukemia
04-03
Other (Myeloma etc.)
Oral / Poster
05.
Breast Cancer
05-01
Early Breast Cancer / Perioperative Therapy
05-02
Metastatic Breast Cancer
Oral / Poster
06.
Gynecologic Cancer
06-01
Gynecologic Cancer
Oral / Poster
07.
Genitourinary Cancer
07-01
Genitourinary Cancer
Oral / Poster
08.
Head and Neck Cancer
08-01
Head and Neck Cancer
Oral / Poster
09.
Rare Cancer / Cancer of Unknown Primary
09-01
Pediatric Oncology
09-02
Central Nervous System Tumors
09-03
Endocrine Cancer, Thyroid Cancer, Neuroendocrine Tumor
09-04
Skin Cancer
09-05
Sarcoma
09-06
Germ Cell Tumor
09-07
Cancer of Unknown Primary
09-08
Other
Oral / Poster
10.
Translational Research / Clinical Pharmacology
10-01
Basic Research
10-02
Clinical Pharmacology
10-03
Innovative Drug Research & Development
10-04
Molecular Diagnostics / Genomic Medicine
10-05
Translational Research
10-06
Companion Diagnostics
10-07
Developmental Therapeutics
10-08
Other
Oral / Poster
11.
Palliative Care / Symptom Management
11-01
Palliative Medicine
11-02
Symptom Management
11-03
Oral Care for Cancer Patients
11-04
Psycho-Oncology
11-05
Other
Oral / Poster
12.
Cross-sectional Program
12-01
Radiation Oncology
12-02
Diagnostic Imaging
12-03
Familial and Hereditary Cancer
12-04
Epidemiology
12-05
Cancer Prevention
12-06
Immunobiology and Immunotherapy
12-07
Drug Therapy
12-08
Other
Oral / Poster
13.
Multidisciplinary Team Program
13-01
Interdisciplinary Approach to Cancer Care
13-02
Rehabilitation
13-03
Outpatient Chemotherapy
13-04
Professional Oncology Education
13-05
Oncology Nursing
13-06
Other
Oral / Poster
14.
Clinical Trial Facilitation Program
14-01
Biostatistics
14-02
Clinical Trial Support
14-03
Trials in Progress
14-04
Research Ethics
14-05
Health Policy / Regulatory Affairs / Reimbursement
14-06
Health Technology Assessment / Health Economics
14-07
Other
Oral / Poster
15.
Patient Advocacy / Survivorship
15-01
Patient Advocacy
15-02
Survivorship
15-03
Geriatric Oncology
15-04
Community Cancer Care
15-05
Adolescents and Young Adults with Cancer
15-06
Other
Oral / Poster
16.
Medical Case Report
16-01
Rare Cancer
16-02
Lung
16-03
Gastrointestinal Tract
16-04
Hematologic Malignancies
16-05
Breast
16-06
Solid Cancers
Poster
17.
COVID-19 and cancer
17-01
COVID-19 and cancer
Oral / Poster
18.
Miscellaneous
18-01
Miscellaneous
Oral / Poster
(a) Abstracts submitted under the “Trials in Progress” category (14-03) will be posted on the program application and handed out to the participants at the venue on the day of the session.

Abstract Young Investigator Award

  • Age limitation: The first author must be under the age 40 (as of March 18, 2023)
  • Once you are nominated as a candidate, you will be requested to submit an electronic data (Powerpoint presentation slides) for review in December 2022. Details will be notified to nominees.
  • If you would like to be reviewed as a candidate, please check the box to be reviewed as the candidate for the Abstract Young Investigator Award.

Late-breaking Abstracts

JSMO2023 would like to deepen discussions based on the latest research results. We accept such abstracts as "Late-breaking abstracts".

If you are applying for Late-breaking abstracts, please select "Yes" for the question, "Are you applying for late-breaking abstracts?" and submit an outline and predicted results of your research as interim registration in the abstract text box.
The submission for the final, updated late-breaking data is planned to open in early December, and run till late December 2022.

*
The accepted results are not influenced even if the actual research results were different from your prediction.

Presidential Session

JSMO2023 will select abstracts to be presented in "Presidential Sessions" from the submitted abstracts this year instead of usual Plenary Session. The selection flow is as follows.

Step 1:
The program committee members recommend the following number of abstracts from each category.
38 abstracts in total: 6 abstracts from each Gastrointestinal Cancer and Lung Cancer /Thoracic Cancer, and each 2 abstracts from other category.

Step 2:
Congress president selects 12 abstracts out of 38 abstracts, and the final selection will be made at the program committee.

Highlight of the Day

Of all the presentations on each day, those with the greatest impact will be selected for review the day after the presentation.

Travel Award

Abstracts submitted by young researchers from outside Japan will be reviewed by the JSMO2023 committee members. Those selected presenters will be awarded partial travel grant for their outstanding works. Abstracts authors are encouraged to apply for Travel Award as outlined below:

Award Details

  • JPY 50,000–100,000 of travel support to investigators from Asia (depending on the quality of abstract).
  • JPY 150,000 of travel support to investigators from others.
  • Congress registration to JSMO2023 is waived
  • Hotel accommodation while you stay in Japan (Single room for up to four nights).
Note: To qualify for the travel award, you must be free of any commercial grants or support.

Application Acceptance Period

Noon, Wednesday, June 15, 2022 – Noon, Friday, September 30, 2022, Japan Standard Time (same as the application period for JSMO2023 abstracts)

Eligible Applicants

  • Applicants must be young overseas doctors/researchers, who live outside of Japan, age 45 years old or younger, as of March 18, 2023 (the last day of JSMO2023).
  • Applicants receiving commercial grant support or financial assistance are ineligible.

How to Apply

Please apply by submitting your abstract from the Submission Page (click the "Submit" button).

Award Notification

Recipients will be notified by e-mail in the middle December 2022.

Publication in "Annals of Oncology"

Abstracts (oral/ poster) submitted in English for JSMO2023 will be published in ESMO/JSMO Scientific Journal, supplement to "Annals of Oncology" (Elsevier).
If you wish to have your abstract published in "Annals of Oncology," please select "Yes".

However, in case that there is any possibility of duplicate publication or encore publication, please refrain from selecting "Yes".

*
Terms to be published in Journal "Annals of Oncology" as to poster presentation:

Oral presentations are free of charge but poster presentations are required 5,000JPY of the posting fee of "Annals of Oncology" in addition to the Congress registration fee.

You can cancel publication of the journal after the acceptance notice.
We will contact you to confirm your final intention when the presentation style is decided.

Disclosure of Conflict of Interest at 2023 the Japanese Society of Medical Oncology Annual Meeting

The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2019 - December 31, 2021.

COI Disclosure Information

COI Policy (in revision)
Detailed Enforcement Regulations of COI (in revision)

For oral presentation, please use the slide below as a template to disclose conflict of interest.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.

Template of slide

1 If your study for this presentation is supported by research funds
2 If you are or have been an employee of a company and / or a profit-making organization related to medicine
3 If you have earned > ¥1,000,000 / year as an officer or advisor of a company and/or a profit-making organization related to medicine
4 If you hold > 5% of the stock of a company and/or a profit-making organization related to medicine, or receive dividends > ¥1,000,000/year
5 If you have earned > ¥1,000,000/year as a patent fee from a company and / or a profit-making organization related to medicine
6 If you have earned > ¥500,000/year as a lecture fee from a company and / or a profit-making organization related to medicine
7 If you have earned > ¥500,000/year as a manuscript fee from a company and / or a profit-making organization related to medicine
8 If you have received > ¥1,000,000/year as research expenses from a company and / or a profit-making organization related to medicine
9 If you have received > ¥1,000,000/year as a certain contribution from a company and / or a profit-making organization related to medicine
10 If you are or have been involved in a certain endowed chair funded by a company and / or a profit-making organization related to medicine
11 If you have earned > ¥1,000,000/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company and / or a profit-making organization related to medicine
12 If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research) equivalent to > ¥50,000/year from a company and / or a profit-making organization related to medicine
13 If you are a representative of an organization for clinical study which receives research expenses (donation, contract, others) from a company and/or a profit-making organization related to medicine

To view the PDF files, you may need, "Adobe Reader " (Download Adobe Reader)

Inquiries regarding COI disclosure

The Secretariat of the Japanese Society of Medical Oncology
E-mail: support[A]jsmo[D]or[D]jp( Please change [A]to @ and [D] to . )

Ethical Principles for Declaring Ethical Matters of your Abstract

In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., JSMO asks you to declare the following items:

The content of your declaration will not affect the acceptance or rejection of your abstract.Please submit to the following:

  1. Does your study include medical research on human subjects, human material or human data? *Required
  2. Does your study comply with the Declaration of Helsinki?
  3. Was your study approved by an institutional review board before starting the research?

Abstract Submission

If you are Japanese, please declare your COI and
submit your abstract to the Japanese website.

How to Submit an Abstract

All abstracts must be submitted via web abstract submission system “LaCool”.
Please follow the steps below to register and create your own “My LaCool” account for submission.

  1. Click “Abstract Submission” button below to create a “My LaCool” account by registering your personal information. To complete your account setting, access via registration URL on the automatic delivery mail sent to your registered email address, set up a password and press “Save” button.
    *
    You will see your registered email address is used as an original log-in ID. The original log-in ID can be changed when you set up a password.
  2. Once your account is set up, press “Return to Top Page (My LaCool)”.
    You can register your abstract from “New Submission of Papers” button.
  3. Submit abstracts that are prepared according to the guidelines shown below and press “Save” to complete the submission.
  4. After the submission is completed, you will receive an automatic delivery mail sent to the registered email address. If you are unable to receive the automatic delivery mail, please go back to the submission page and make sure the submission is completed by the “Save” button.
  5. To confirm/modify/delete/add abstracts during the abstract submission period, log in to “My LaCool”, click your abstract registration number (e7XXXX). After making any changes, please make sure to press “Save” to save added/edited information, or those changes will be discarded.
*
Please set up your e-mail account settings to accept emails from “lacool-send-only@convention.co.jp” and “endai-jsmo2023@convention.co.jp”.
*
It is best to avoid using free email services (gmail, hotmail, etc.), if possible.
*
Notification of Acceptance/Rejection will be sent to the registered e-mail address. To avoid a failed delivery, make sure that the email address is correct and is not mistyped or misspelt.
*
Please make sure to keep your password and log-in ID by yourself. We cannot provide new passwords or ID in any circumstances.

Guideline

We accept abstracts submitted online only through the submission system.
You may enter the submission page from the "Abstract Submission" button at the bottom of this page.

  1. Author information and abstracts must be submitted in English.
  2. Abstract title must be up to 120 single-byte characters. (including spaces)
  3. Abstract text must be up to 2,000 single-byte characters. (including spaces)
  4. The maximum of 20 authors (first author & co-authors) can be registered.
  5. The maximum of 20 affiliations (including the affiliation of the first author) can be registered.
  6. Please structure your abstract as follows:
    Background:
    Methods:
    Results:
    Conclusion:
  7. Any chart or diagram cannot be included.
  8. In the registration page, you will be asked to enter the information such as "Application for Late-breaking abstracts", "Application for Travel Awards", "Publication in Annals of Oncology" as well as COI information.
*
It is recommended that you prepare your abstract text by Word / text file in advance, and then copy it on the registration page.

Acceptance/Rejection Notification

All submitted abstracts will be reviewed by the Peer Review Committee and decided comprehensively based on the study contents, ethical aspects, and etc. You may choose the presentation style (oral or poster) when you submit an abstract. However, please understand that the congress president will make a final decision on the presentation style, presentation session, as well as acceptance/rejection.

Notification of acceptance/rejection will be sent to the first author by email in the middle of December, 2022.

Abstract Submission

Inquiries for Abstract Submission

c/o Japan Convention Services, Inc.
Fukuoka Daido Seimei Bldg. 12-33, Nishinakasu, Chuoku,
Fukuoka, 810-0002, Japan
E-mail: endai-jsmo2023[A]convention[D]co[D]jp( Please change [A]to @ and [D] to . )

Secretary

Department of Oncology and Social Medicine,
Graduate School of Medical Sciences, Kyushu University
3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, JapanJapan

Congress Secretariat

Japan Convention Services, Inc.
Fukuoka Daido Seimei Bldg. 12-33, Nishinakasu, Chuoku,
Fukuoka, 810-0002, Japan
E-mail: jsmo2023[A]convention[D]co[D]jp( Please change [A]to @ and [D] to . )

Back to Top